• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Cardiology Research and Practice >Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
【2h】

Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?

机译：保留射血分数的心力衰竭的当前治疗方法：我们应该增加剩余生命还是增加剩余生命？

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

According to the ejection fraction, patients with heart failure may be divided into two different groups: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More importantly, despite decline in mortality after treatment in regard to current guideline in patients with heart failure with reduced ejection fraction, there are still no trials resulting in improved outcome in patients with heart failure with preserved ejection fraction so far. Thus, novel pathophysiological mechanisms are under development, and other new viewpoints, such as multiple comorbidities resulting in increased non-cardiac deaths in patients with heart failure and preserved ejection fraction, were presented recently. In this review, we will focus on the tested as well as the promising therapeutic options that are currently studied in patients with heart failure with preserved ejection fraction, along with a brief discussion of pathophysiological mechanisms and diagnostic options that are helpful to increase our understanding of novel therapeutic strategies.
机译：根据射血分数，心力衰竭患者可分为两组：射血分数保持或降低的心力衰竭。近年来，越来越多的研究表明，这两组的死亡率和发病率几乎相等。更重要的是，尽管目前射血分数降低的心力衰竭患者的治疗指南后死亡率有所下降，但迄今为止，尚无任何试验能使射血分数保持不变的心力衰竭患者的预后得到改善。因此，新的病理生理机制正在开发中，并且最近提出了其他新观点，例如多种合并症导致心力衰竭患者的非心脏死亡增加和射血分数得以保留。在这篇综述中，我们将重点介绍目前针对射血分数得以保留的心力衰竭患者进行的测试以及有前途的治疗选择，并简要讨论有助于提高我们对以下方面的了解的病理生理机制和诊断选择新颖的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号